Jeffery Kelly

from Wikipedia, the free encyclopedia

Jeffery W. Kelly (born August 23, 1960 in Medina , New York ) is an American biochemist . He is Professor of Chemical Biology at the Scripps Research Institute (Skaggs Institute).

Jeffery Kelly received his bachelor's degree in chemistry from the State University of New York at Fredonia in 1982 and was promoted cyclodehydrations in 1986 with Slayton A. Evans at the University of North Carolina with the thesis I. The mechanism, stereochemistry, and scope of dioxyphosphorane; II. Oxygen-17 NMR studies directed towards elucidating the structure and dynamics of oxygenated organosulfur and organosilicon compounds doctorate . As a post-doctoral student he was at Rockefeller University with Emil Thomas Kaiser . In 1989 he became Assistant Professor, 1994 Associate Professor and 1997 Professor at Texas A&M University . From 1997 he was a professor at the Scripps Research Institute.

It deals with the mechanism of protein folding in the laboratory and in the cell, the enzyme pathways involved and errors that occur and lead to diseases such as Alzheimer's disease and other amyloidoses and Parkinson's disease due to loss of function or toxic effects . In his laboratory, he develops drugs (with targeted chemical synthesis of small molecules) that intervene in the processes that lead to faulty protein folding.

Kelly is the Lita Annenberg Hazen Professor of Chemistry and Director of the Laboratory for Molecular and Experimental Medicine at the Scripps Research Institute. From 2000 to 2006 he was Vice President (Academic Affairs), 2000 to 2008 Dean for Graduate Studies and from 2008 to 2010 he was Chairman of the Board of Trustees of the Scripps Research Institute.

In 2003 he co-founded FoldRx Pharmaceuticals in Boston. The company developed the drug Tafamidis (trade name Vyndaqel ) for familial amyloid polyneuropathy (FAP) . Kelly was President of the Protein Society from 2005 to 2007.

In 2012 he received the American Chemical Society's Ralph F. Hirschmann Award in Peptide Chemistry , the American Peptide Society's Vincent du Vigneaud Award in 2008, and the National Institutes of Health's Merit Award in 2006 . In 2001 he was an Arthur C. Cope Scholar . In 2016 he was elected a member of the American Academy of Arts and Sciences and received the Gabbay Award . For 2017 he was awarded the Chemical Pioneer Award .

Web links

Individual evidence

  1. ↑ biographical data, publications and Academic pedigree of Jeffery W. Kelly at academictree.org, accessed on February 15 2018th
  2. ↑ Steven M. Johnson, Stephen Connelly, Colleen Fearns, Evan T. Powers, Jeffery W. Kelly: The Transthyretin Amyloidoses: From Delineating the Molecular Mechanism of Aggregation Linked to Pathology to a Regulatory-Agency-Approved Drug . In: J Mol Biol . tape 421 , no. 2-3 , 2012, p. 185–203 , doi : 10.1016 / j.jmb.2011.12.060 , PMID 22244854 .
  3. ↑ Book of Members 1780 – present, Chapter K. (PDF; 670 kB) In: American Academy of Arts and Sciences (amacad.org). Retrieved September 23, 2017 (English).
personal data
SURNAME Kelly, Jeffery
ALTERNATIVE NAMES Kelly, Jeffery W.
BRIEF DESCRIPTION American biochemist
DATE OF BIRTH 23rd August 1960
PLACE OF BIRTH Medina , New York